B. Riley Predicts Weaker Earnings for Trevi Therapeutics

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities researchers at B. Riley lowered their Q2 2025 earnings per share estimates for Trevi Therapeutics in a research report issued on Wednesday, March 19th. B. Riley analyst M. Mamtani now forecasts that the company will earn ($0.16) per share for the quarter, down from their prior estimate of ($0.14). B. Riley has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. B. Riley also issued estimates for Trevi Therapeutics’ Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($1.17) EPS.

TRVI has been the subject of a number of other research reports. Needham & Company LLC reduced their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $12.50 price target on shares of Trevi Therapeutics in a report on Wednesday. Oppenheimer boosted their price target on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. D. Boral Capital reissued a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday. Finally, Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $9.00 to $29.00 in a report on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $17.56.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock opened at $6.47 on Friday. The stock has a market cap of $497.32 million, a PE ratio of -14.70 and a beta of 0.90. Trevi Therapeutics has a one year low of $2.30 and a one year high of $7.39. The stock has a fifty day moving average of $4.60 and a 200 day moving average of $3.75.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01.

Institutional Investors Weigh In On Trevi Therapeutics

A number of hedge funds have recently made changes to their positions in TRVI. GSA Capital Partners LLP purchased a new stake in shares of Trevi Therapeutics in the third quarter worth about $409,000. Oppenheimer & Co. Inc. lifted its position in shares of Trevi Therapeutics by 34.7% in the third quarter. Oppenheimer & Co. Inc. now owns 81,947 shares of the company’s stock worth $274,000 after buying an additional 21,128 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Trevi Therapeutics in the third quarter worth about $63,000. BNP Paribas Financial Markets lifted its position in shares of Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after buying an additional 6,764 shares in the last quarter. Finally, Acuta Capital Partners LLC lifted its position in shares of Trevi Therapeutics by 11.7% in the third quarter. Acuta Capital Partners LLC now owns 290,500 shares of the company’s stock worth $970,000 after buying an additional 30,500 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Trevi Therapeutics

In other news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now owns 76,900 shares of the company’s stock, valued at $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 24.37% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.